Log In
BCIQ
Print this Print this
 

IDH305

  Manage Alerts
Collapse Summary General Information
Company Novartis AG
DescriptionIsocitrate dehydrogenase 1 (IDH1) inhibitor
Molecular Target Isocitrate dehydrogenase 1 (IDH1)
Mechanism of ActionIsocitrate dehydrogenase 1 (IDH1) inhibitor
Therapeutic ModalityActive immunotherapy
Latest Stage of DevelopmentPhase I
Standard Indication Cancer (unspecified)
Indication DetailsTreat advanced malignancies harboring IDH1R132 mutations
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today